secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revium Rx. (RVRC)
CIK:        0001839140
Form:       8-K
Filed at:   2026-06-22T13:42:07+00:00
Accession:  0001213900-26-070415
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Revium Rx COO, President and Director Inna Martin resigns due to differences in expectations
--------------------------------------------------------------------------------

- Inna Martin resigned as Director, COO, and President effective June 16, 2026, due to differences in expectations with the company.
- Separation agreement: employment and consultancy with Revium Ltd. ends Sep 10, 2026; vested stock option exercise period extended to Sep 30, 2028 for up to 2,440,000 shares.
- Shares and options subject to sale restrictions per Separation Agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1839140/000121390026070415/0001213900-26-070415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1839140/000121390026070415/ea0295431-8k_revium.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-070415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer